Shareholder Alert: The Ademi Firm investigates whether Amicus Therapeutics, Inc. is obtaining a Fair Price for its Public Shareholders

Core Viewpoint - The Ademi Firm is investigating Amicus for potential breaches of fiduciary duty related to its transaction with BioMarin, which involves a significant cash payout to shareholders [1][3]. Group 1: Transaction Details - Amicus shareholders will receive $14.50 per share in an all-cash transaction valued at approximately $4.8 billion [2]. - The transaction includes substantial benefits for Amicus insiders as part of change of control arrangements [2]. Group 2: Investigation Focus - The transaction agreement imposes a significant penalty on Amicus if it accepts a competing bid, which may limit competing transactions unreasonably [3]. - The investigation will assess whether the Amicus board of directors is fulfilling their fiduciary duties to all shareholders [3].